Effect of following treat-to-target strategies on remission outcomes 3 months later*
| DAS44 remission (OR (95% CI)) | DAS28-ESR remission (OR (95% CI)) | ACR/EULAR Boolean remission (OR (95% CI)) | CDAI remission (OR (95% CI)) | SDAI remission (OR (95% CI)) | |
| T2T | 1.03 (0.92 to 1.16) | 1.03 (0.91 to 1.16) | 1.16 (1.01 to 1.34) | 1.29 (1.12 to 1.49) | 1.24 (1.08 to 1.41) |
| T2T without corticosteroids | 1.07 (0.95 to 1.20) | 1.11 (0.98 to 1.26) | 1.23 (1.06 to 1.42) | 1.37 (1.18 to 1.59) | 1.34 (1.17 to 1.53) |
| T2T-REM less strict | 1.06 (0.94 to 1.19) | 1.07 (0.95 to 1.21) | 1.32 (1.13 to 1.53) | 1.43 (1.22 to 1.67) | 1.34 (1.17 to 1.54) |
| T2T-LDA | 1.26 (1.10 to 1.44) | 1.36 (1.17 to 1.56) | 1.27 (1.09 to 1.47) | 1.39 (1.18 to 1.64) | 1.36 (1.17 to 1.59) |
T2T without corticosteroids: without considering corticosteroids in treatment intensification. T2T-REM less strict: considering T2T as adequate as long as the target, DAS44 remission, is met, regardless of whether treatment nevertheless intensified or not.
*All models adjusted for age, gender, disease duration and country. T2T was considered being followed: (i) if a patient had already a disease activity score below the target (DAS <1.6; DAS <2.4 for LDA definition) and treatment was correctly not intensified; or (ii) if treatment was intensified on a DAS ≥1.6 (or DAS ≥2.4 for LDA definition).
ACR, American College of Rheumatology; CDAI, Clinical Disease Activity Index; DAS44, 44-joint disease activity score; DAS28-ESR, 28-joint disease activity score (with ESR); ESR, erythrocyte sedimentation rate; EULAR, European League Against Rheumatism; SDAI, Simple Disease Activity Index; T2T, treat-to-target; T2T-LDA, T2T-low disease activity; T2T-REM, T2T-remission.